Premium
Fixed‐Dose Combination Diuretics in Congestive Heart Failure: An Evaluation
Author(s) -
LEVY BENJAMIN
Publication year - 1979
Publication title -
the journal of clinical pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1979.tb01645.x
Subject(s) - furosemide , diuretic , spironolactone , hydrochlorothiazide , heart failure , triamterene , medicine , aldosterone , blood urea nitrogen , pharmacology , plasma renin activity , cardiology , urology , renin–angiotensin system , blood pressure , kidney
Thirty-two patients with congestive heart failure were studied for their clinical and biochemical responses to the administration of two combination diuretic products (hydrochlorothiazide/spironolactone and hydrochlorothiazide/triamterene) and the single entity diuretic furosemide. Data from these studies revealed the following: 1. Comparison of the patients on furosemide with those receiving the combination products showed no difference in serum potassium or 24-hour potassium excretion. 2. Significant changes in blood urea nitrogen, plasma renin activity, and urinary aldosterone excretion were noted with both fixed-combination medications but not with furosemide. 3. The combination diuretics offered no clinical benefits over the single agent furosemide. 4. Therapy is best served by the use of a single effective diuretic agent for the treatment of most patients with congestive heart failure.